Relevant bibliographies by topics / Hepatitis Treatment Victoria

Academic literature on the topic 'Hepatitis Treatment Victoria'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hepatitis Treatment Victoria.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hepatitis Treatment Victoria"

1

Glenister, Kristen, William Kemp, Dunya Tomic, David Simmons, and Stuart Roberts. "Prevalence of Hepatitis C and treatment uptake in regional Victoria." Australian and New Zealand Journal of Public Health 44, no. 6 (November 30, 2020): 514–16. http://dx.doi.org/10.1111/1753-6405.13040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Adamson, E., N. Yussf, and E. Schreiber. "Using Liver Cancer Prevention Messages to Scale up the Diagnosis and Treatment of People Living With Hepatitis B." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 132s. http://dx.doi.org/10.1200/jgo.18.32800.

Full text
Abstract:
Background and context: Chronic hepatitis B (CHB) is a major public health issue in Australia, affecting an estimated 238,000 people. If not appropriately managed, chronic hepatitis B infection can cause cirrhosis and liver cancer. Liver cancer has the fastest increasing incidence rate of all cancers in Australia, and its survival is among the lowest. To reduce the burden of liver cancer, more people with CHB need to be diagnosed and treated. The majority of people living in Australia with CHB (61%) were born overseas, and research indicates people have low levels of understanding about hepatitis B, and its link to liver cancer. Cancer Council Victoria developed several communication campaigns to increase testing and diagnosis for hepatitis B in the Vietnamese and south Sudanese communities living in Victoria. Aim: •To raise awareness about hepatitis B and the link to liver cancer in the Vietnamese and south Sudanese community •To increase understanding about diagnosis, vaccination and management •To mobilize the community to talk to their trusted GP about hepatitis and to be tested. Strategy/Tactics: The campaign strategy was designed to address the knowledge barriers to testing for these two communities. To inform the strategy, qualitative focus groups and community interviews were used to identify perceptions of hepatitis B and liver cancer, as well as the barriers and motivators to testing. Both communities identified their local doctor as a trusted source of health information. Two media campaigns were developed featuring a known doctor from each community. An additional campaign was tailored specifically for young south Sudanese people using hip hop music as method of disseminating key messages about liver cancer prevention. Program/Policy process: The campaigns were designed by the Screening, Early Detection and Immunization Team at Cancer in Council Victoria, Australia. Outcomes: Digital metrics and face to face interviews with community members, nurses and doctors were used to assess the impact of the campaigns. Evaluation results also indicated people did visit their doctor to talk about hepatitis B. The success in motivating people to see their doctor was attributed to the campaigns featuring a message about liver cancer being caused by hepatitis B, and it being led by a known and respected doctor from their own community. What was learned: Cancer organizations can target liver cancer prevention efforts to · increase awareness about liver cancer and hepatitis B in at risk communities; · motivate at risk people to visit their doctor for hepatitis B testing, vaccination and treatment by linking the prevention of liver cancer to hepatitis treatment; · tailor communications to the specific needs of different culturally diverse communities; · collaborate closely with communities from culturally diverse backgrounds to ensure campaign messages and calls to action are culturally appropriate.
APA, Harvard, Vancouver, ISO, and other styles
3

Iddi, Shabani, Caroline A. Minja, Vitus Silago, Asteria Benjamin, Jastine Mpesha, Shimba Henerico, Benson R. Kidenya, Stephen E. Mshana, and Mariam M. Mirambo. "High Human Immunodeficiency Virus (HIV) Viral Load and Coinfection with Viral Hepatitis Are Associated with Liver Enzyme Abnormalities among HIV Seropositive Patients on Antiretroviral Therapy in the Lake Victoria Zone, Tanzania." AIDS Research and Treatment 2019 (June 2, 2019): 1–6. http://dx.doi.org/10.1155/2019/6375714.

Full text
Abstract:
Background. Liver enzymes abnormalities have been found to be common among patients on antiretroviral treatment (ART). Apart from the effects of ART on these changes, other factors that can potentially contribute to the abnormal levels of these enzymes have been found to vary in different geographical locations. This study investigated factors associated with liver enzymes abnormalities among human immunodeficiency virus (HIV) infected individuals on ART from the Lake Victoria zone, Tanzania. Methods. A cross-sectional study involving a total of 230 sera from HIV seropositive patients from different regions of the Lake Victoria zone was carried out in July 2017. All samples with required variables/parameters such as age, sex, ART regimen, and residence were serially included in the study. Hepatitis B virus (HBV) and Hepatitis C virus (HCV) detection and liver enzymes assays (alanine transaminase (ALAT) and aspartate transaminase (ASAT)) were assessed following the standard procedures. Data were analyzed by using STATA version 13. Results. The median age of the study participants was 38 (interquartile range [IQR]:30-48) years. The overall prevalence of abnormal liver enzymes was 43.04% (99/230, 95% CI: 36.6-49.3). A total of 26.09% (60/230) had elevated ASAT while 23.9% (55/230) patients had elevated ALAT levels. ASAT levels were significantly high among patients with high HIV viral load (P= 0.002) while ALAT levels were significantly high among those coinfected with hepatitis C virus (P=0.017) and hepatitis B virus (P<0.001). Conclusion. A significant proportion of HIV seropositive individuals on ART have abnormal levels of liver enzymes, which is significantly associated with high HIV viral load and viral hepatitis. This calls for the need to emphasize screening of viral hepatitis and provision of appropriate management among HIV seropositive individuals in this setting.
APA, Harvard, Vancouver, ISO, and other styles
4

Grebely, Jason, Marc Bilodeau, Jordan J. Feld, Julie Bruneau, Benedikt Fischer, Jennifer F. Raven, Eve Roberts, et al. "The Second Canadian Symposium on Hepatitis C Virus: A Call to Action." Canadian Journal of Gastroenterology 27, no. 11 (2013): 627–32. http://dx.doi.org/10.1155/2013/242405.

Full text
Abstract:
In Canada, hepatitis C virus (HCV) infection results in considerable morbidity, mortality and health-related costs. Within the next three to 10 years, it is expected that tolerable, short-duration (12 to 24 weeks) therapies capable of curing >90% of those who undergo treatment will be approved. Given that most of those already infected are aging and at risk for progressive liver disease, building research-based interdisciplinary prevention, care and treatment capacity is an urgent priority. In an effort to increase the dissemination of knowledge in Canada in this rapidly advancing field, the National CIHR Research Training Program in Hepatitis C (NCRTP-HepC) established an annual interdisciplinary Canadian Symposium on Hepatitis C Virus. The first symposium was held in Montreal, Quebec, in 2012, and the second symposium was held in Victoria, British Columbia, in 2013. The current article presents highlights from the 2013 meeting. It summarizes recent advances in HCV research in Canada and internationally, and presents the consensus of the meeting participants that Canada would benefit from having its own national HCV strategy to identify critical gaps in policies and programs to more effectively address the challenges of expanding HCV screening and treatment.
APA, Harvard, Vancouver, ISO, and other styles
5

Hellard, Margaret E., Rebecca Jenkinson, Peter Higgs, Mark A. Stoové, Rachel Sacks‐Davis, Judy Gold, Matthew Hickman, Peter Vickerman, and Natasha K. Martin. "Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia." Medical Journal of Australia 196, no. 10 (June 2012): 638–41. http://dx.doi.org/10.5694/mja11.10981.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

MacParland, Sonya A., Marc Bilodeau, Jason Grebely, Julie Bruneau, Curtis Cooper, Marina Klein, Selena M. Sagan, et al. "The 3rd Canadian Symposium on Hepatitis C Virus: Expanding Care in the Interferon-Free Era." Canadian Journal of Gastroenterology and Hepatology 28, no. 9 (2014): 481–87. http://dx.doi.org/10.1155/2014/704919.

Full text
Abstract:
Hepatitis C virus (HCV) currently infects approximately 250,000 individuals in Canada and causes more years of life lost than any other infectious disease in the country. In August 2011, new therapies were approved by Health Canada that have achieved higher response rates among those treated, but are poorly tolerated. By 2014/2015, short-course, well-tolerated treatments with cure rates >95% will be available. However, treatment uptake is poor due to structural, financial, geographical, cultural and social barriers. As such, ‘Barriers to access to HCV care in Canada’ is a crucial topic that must be addressed to decrease HCV disease burden and potentially eliminate HCV in Canada. Understanding how to better care for HCV-infected individuals requires integration across multiple disciplines including researchers, clinical services and policy makers to address the major populations affected by HCV including people who inject drugs, baby boomers, immigrants and Aboriginal and/or First Nations people. In 2012, the National CIHR Research Training Program in Hepatitis C organized the 1st Canadian Symposium on Hepatitis C Virus (CSHCV) in Montreal, Quebec. The 2nd CSHCV was held in 2013 in Victoria, British Columbia. Both symposia were highly successful, attracting leading international faculty with excellent attendance leading to dialogue and knowledge translation among attendees of diverse backgrounds. The current article summarizes the 3rd CSHCV, held February 2014, in Toronto, Ontario.
APA, Harvard, Vancouver, ISO, and other styles
7

Selfridge, Marion, Evan B. Cunningham, Rozalyn Milne, Anne Drost, Tamara Barnett, Karen Lundgren, Kellie Guarasci, Jason Grebely, and Chris Fraser. "Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada." International Journal of Drug Policy 72 (October 2019): 106–13. http://dx.doi.org/10.1016/j.drugpo.2019.03.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ali, Qazi Masroor, Syed Hashim Raza, Ali Imran, Saba Anjum, and Maria Masroor. "Efficacy and safety of sofosbuvir plus ribavirin in treatment-naive chronic hepatitis c genotype 3 patients of South Punjab, Pakistan." International Journal of Research in Medical Sciences 8, no. 12 (November 27, 2020): 4242. http://dx.doi.org/10.18203/2320-6012.ijrms20205297.

Full text
Abstract:
Background: To evaluate the efficacy and safety of sofosbuvir (SOF) plus ribavirin (RIB) in naive patients with chronic HCV genotype 3. The study design was open label, quasi experimental study. The study was conducted at Medical Outpatient Department of Medical Unit-1, Bahawal Victoria Hospital, affiliated with Quaid e Azam Medical College (QAMC), Bahawalpur, from April 2016 to June 2019.Methods: A total of 627 treatment-naive patients, aged above 18 years, with chronic Hepatitis C virus (HCV) genotype 3 infection were enrolled. SOF as 400 mg once a day plus weight-based RIB (1000 mg/day <75 kg and 1200 mg/day >75 kg) was given to all the study participants for 24 weeks. Qualitative polymerase chain reaction (PCR) for HCV ribonucleic acid (RNA) were done at 4 weeks to note the rapid virological response (RVR) whereas end of treatment response (ETR) was recorded at 24 weeks and sustained virological response (SVR) was noted 3 months after completion of treatment.Results: By 4th week, PCR of 524 (83.6%) patients was available, out of which, 492 (93.9%) had undetectable HCV RNA. By the end of treatment (24 weeks), PCR of 401 (64.0%) patients was available, out of which, 393 (98.0%) had undetectable HCV RNA. Data of 291 (46.4%) patients was available for SVR, 274 (94.1%) had undetectable HCV RNA. Weakness and fatigue turned out to be the commonest side effects, observed in 236 (37.6%) patients.Conclusions: Sofosbuvir was found to have good efficacy and safety in the local population of South Punjab having treatment-naïve chronic HCV genotype 3 infection.
APA, Harvard, Vancouver, ISO, and other styles
9

Selfridge, Marion, Tamara Barnett, Kellie Guarasci, Karen Lundgren, Anne Drost, and Chris Fraser. "“Like what? You think I have that?”-Impact of stigma on pharmacy-based identification and treatment of hepatitis C in Victoria, British Columbia." Journal of Hepatology 77 (July 2022): S240—S241. http://dx.doi.org/10.1016/s0168-8278(22)00853-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ehsani, Jonathon P., Trang Vu, and Maria Karvelas. "Exploring the need for hepatology nurses and allied health professionals in Victorian liver clinics." Australian Health Review 30, no. 2 (2006): 211. http://dx.doi.org/10.1071/ah060211.

Full text
Abstract:
Objective: To examine the need for hepatology nurses and allied health professionals in Victorian liver clinics to meet the increasing demand from people seeking treatment for hepatitis C infection. Design: We reviewed the literature, analysed data from nine Victorian liver clinics, and conducted a qualitative rapid assessment with key stakeholders including hepatology nurses. Participants: Fourteen key stakeholders including clinicians and directors of liver clinics were invited to take part in interviews; two declined to participate. All ten members of the Victorian Hepatology Nurses Group were invited to participate in a focus group discussion, and six attended. Results: Participants reported that hepatology nurses played a critical role in improving treatment uptake and compliance, in particular, in educating, counselling and managing treatment for people with hepatitis C infection. Psychiatric and social work staff assisted patients to overcome side effects associated with treatment. Interpreters increased access for those from culturally and linguistically diverse communities. Conclusions: Hepatology nurses and allied health professionals are central to enhancing treatment outcomes for people who are infected with hepatitis C. Further research is necessary to estimate the number of nurses and allied health professionals required to meet the current and future needs of people receiving treatment for hepatitis C infection.
APA, Harvard, Vancouver, ISO, and other styles
More sources
You might also be interested in the extended bibliographies on the topic 'Hepatitis Treatment Victoria' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography